Introduction
Angiogenesis, the development of a microvascular bed, is required for a variety of important physiological processes, such as normal growth and differentiation, wound healing, compensatory hyperplasias, corpus luteum formation, etc. (1) (2) (3) . The new blood vessels provide an enhanced supply of oxygen and nutrients, which allows the tissues to meet increased metabolic demands, and also carry critical regulatory molecules (4) . However, aberrant angiogenesis can be a significant pathogenic component of a variety of disorders such as cancer, diabetes mellitus, atherosclerosis, or rheumatoid arthritis (1) (2) (3) . In view of the clinical relevance of cancer, an especially large amount of work has been dedicated to tumor angiogenesis (5-7). The new capillaries provide nourishment to the growing tumor and Address correspondence to Napoleone Ferrara Receivedfor publication 24 April 1992 and in revisedform 29 July 1992. also allow the tumor cells to establish continuity with the vasculature of the host. In support of the hypothesis that angiogenesis plays an important role in the development ofa malignancy, it has been recently shown that the acquisition ofan angiogenic phenotype marks the transition from hyperplasia to neoplasia (7) .
Several factors of both peptide and nonpeptide nature have been shown to induce angiogenesis in vivo: epidermal growth factor, transforming growth factor-alpha and beta, tumor necrosis factor-alpha, angiogenin, acidic fibroblast growth factor, basic FGF (bFGF), platelet-derived endothelial cell growth factor, PGE2, and monobutyrin (1) (2) (3) . Recently, a family of endothelial cell mitogens and angiogenic factors known as vascular endothelial growth factor (VEGF)' (8) (9) (10) (11) (12) or vascular permeability factor (13) (14) (15) (16) has been identified and the respective cDNAs have been cloned. By alternative splicing of mRNA, four different molecular species of VEGF are generated. These have 121, 165, 189, and 206 amino acids, respectively (VEGF121, VEGF165, VEGF189, VEGF206) (9, 11, 12, 17) . VEGF165 is the most abundant molecular species in the majority ofcells and tissues ( 1 1, 17) . The two longer forms are characterized by the presence of a 24 amino acid insertion highly enriched in basic residues ("nuclear targeting site"). The two shorter forms are soluble after secretion, while the longer ones are mostly insoluble ( 17) . Recent studies have provided evidence that theflt protein is a receptor for VEGF ( 18) . These factors display several properties which suggest that they may be important and specific mediators of endothelial cell differentiation and angiogenesis. First, VEGF,2, and VEGF165, unlike FGFs or platelet-derived endothelial cell growth factor, which are mostly intracellular (19) (20) (21) , are secreted proteins. Second, VEGFs are endothelial cell-specific mitogens in vitro (8, 10, 2 1 ). Third, VEGF promotes angiogenesis in several in vivo models (9, 14, 22) . Fourth, the VEGF mRNA is expressed in a variety of abundantly vascularized tissues such as pituitary, brain, lung, heart, or kidney ( 12, 23, 24) . In the rat and primate ovary, the expression ofthe VEGF mRNA is temporally and spatially related to the proliferation of capillaries into the corpus luteum, providing circumstantial evidence that VEGF is a physiological mediator of angiogenesis (25, 26) . This hypothesis is supported by recent findings that demonstrate expression of VEGF mRNA in the ventricular neuroectoderm in the mouse embryo, temporally and spatially related to the development of capillaries from the perineural plexus (27) .
An additional property ofthis family of factors is the ability to induce vascular leakage ( 1 [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] as evidenced by blue Evans extravasation in the guinea pig skin-based Miles assay (28) . Vascular permeability factor was identified from the conditioned medium oftumor cell lines on the basis ofthis property. It was proposed that such a factor is a tumor-specific protein, involved in the increased permeability to plasma proteins displayed by tumor vessels ( 13) . It has been suggested that high vascular permeability to proteins such as fibrinogen plays a significant role in the process oftumor angiogenesis and metastasis; an extravascular fibrin gel would provide an optimal substratum for both tumor and endothelial cell growth (29) .
Transfection of mammalian cells with expression vectors carrying specific cDNAs and introduction of such cells into a living host represents an important tool to investigate the in vivo effects ofgene products in general and to test the hypothesis that such gene products may confer on a given cell the ability to grow in vivo in particular (30) (31) (32) (33) . In the present study, we describe the effects ofthe introduction ofexpression vectors which direct the constitutive synthesis ofVEGF in a dihydrofolatereductase (DHFR)-clone of Chinese hamster ovary (CHO) cells. The transfected cells were characterized for their ability to grow in anchorage-dependent or anchorage-independent fashion. We also injected transfected or parental cells into nude mice. The proliferative lesions, which developed from CHO cells expressing VEGF, were characterized for their morphological features and for VEGF expression. The ultrastructure of capillaries within the tumors was also elucidated.
Methods
Reagents. Tissue culture reagents, media, and sera were purchased from Gibco Laboratories (Grand Island, NY) through the Genentech media facility. Tissue culture plates were from Costar Corp. (Cambridge, MA) or Nunc (Kamstrup, Denmark). Recombinant human (rh) VEGF165 was purified from conditioned medium of transfected CHO cells as described (34 (9) was -650 bp. A DHFR-clone of CHO cells (DP,2) was used for transfection. Cells were cultured in 10-cm tissue culture dishes in the presence of low glucose DMEM/F1 2 ( 1:1 ) plus 2% dialyzed fetal bovine serum, 2 mM glutamine, glycine ( 10 mg/ml), hypoxanthine ( 15 mg/ ml), thymidine (5 mg/ ml) (G-H-T) and antibiotics. Subconfluent cultures were transfected with expression vectors carrying VEGF cDNA or vector alone by the calcium phosphate coprecipitation method (36) . 48 h after transfection, cells were placed in selection medium. This was identical to the growth medium except for the absence of G-H-T. After approximately a week, colonies were picked by a pipette tip and transferred into individual wells of24 multiwell plates in the presence of selection medium. Subconfluent clones were screened for their ability to release in the medium mitogenic activity for capillary endothelial cells. Clones which displayed the highest bioactivity were expanded and amplified (37) in the presence of increasing concentrations of methotrexate. Clones proliferating in the presence of 1 gm methotrexate were used in the present study.
Proliferation assays. Mitogenic assays on bovine adrenal cortexderived capillary endothelial cells were performed as previously described (8) . Various aliquots ofconditioned media or rhVEGF165 were added to cells 4-6 h after plating. Cells were counted in a counter after [4] [5] d (Coulter Corp., Hialeah, FL).
To assess the effects of VEGF on the growth of CHO cells, parental or transfected cells were seeded at the density of 20,000/well in 12 multiwell plates in the presence ofDMEM/F12 supplemented with 2% dialyzed fetal bovine serum, G-H-T, 2 mM glutamine, and antibiotics.
Various concentrations of rhVEGF,65 were added in 10-,al aliquots.
Cells were dissociated by exposure to trypsin and counted in a counter after 5 d (Coulter Corp.). To determine proliferation as a function of time, CHO cells were plated in 12 multiwell plates as described above and counted every other day.
VEGF ELISA. 96-well microtiter plates were coated with a monoclonal antibody directed against rhVEGF,65 (mAb 4.6.1.) (38) by incubation at 4°C with 100 ul/well of antibody at 2.5 ,ug/ml in 50 mmol/ liter of sodium carbonate, pH 9.6, and then blocked with 0.5% BSA in PBS for 1 h at room temperature. rhVEGF165 (between 0.78 and 50 ng/ ml) or test samples were added to the coated wells and then incubated for 2 h at room temperature. Plates were then incubated with horseradish peroxidase-labeled monoclonal antibody 3.13.1. (38) . Substrate solution (0.04% o-phenyenediamine dihydrochloride in PBS plus 0.4 ml/liter of 30% hydrogen peroxide) was added to plates. After 15 min in the dark, the reaction was stopped by the addition of 2.25 mol/ liter sulfuric acid and absorbance at 490 nm was determined on a plate reader. Between each step, plates were washed six times with PBS containing 0.1% Tween 20. A standard curve was generated by plotting absorbance vs log of rhVEGF,65 concentration, using a four-parameter nonlinear regression curve fitting program. The limit of sensitivity of the assay was 0.4 ng/tube.
Metabolic labeling ofcells. For metabolic labeling, cells were passaged into 24 multiwell tissue culture plates at the density of 10,000 cells/well. As soon as cells were confluent, they were washed three times with PBS and then incubated for 1 h in the presence ofserum-free methionine-cysteine free DMEM/F12 containing 100 uCi [35S]-methionine. The medium was removed and replaced with fresh serumfree medium containing methionine and cysteine. After 5 h, media were removed and aliquots were subjected to SDS/PAGE gel ( 12.5%), in both reducing and nonreducing conditions. The gel was then dried and processed for fluorography.
Soft agar colony formation assay. The soft agar assay was performed essentially as previously described (39). 4 ml of high glucose DMEM supplemented with 10% FBS, 2 mM glutamine, G-H-T, and antibiotics (complete medium) plus 0.5% (wt/vol) agar (Difco Laboratories, Inc., Detroit, Ml) were added to 60-mm tissue culture dishes and allowed to solidify. 30,000 cells in a 0. l-ml vol were then added slowly, followed by 3 ml of complete medium containing 0.25% agar.
Half of the dishes seeded with parental or vector-transfected cells also received rhVEGF,65 at the final concentration of 20 ng/ml. Cultures were incubated in a humidified atmosphere at 37°C in the presence of 5% CO2. After dorsal areas in a volume of 0.2 ml at various final densities (Table III) . Length and width of tumors were measured twice weekly. After 4-6 wk, animals were killed by CO2 inhalation and tissues were dissected and immersed in the appropriate fixative.
Light level histological examination. The lung, liver, spleen, and injection sites were removed from each animal immediately after euthanasia and immersion-fixed in 10% neutral buffered phosphate formalin. Tissues were processed for paraffin embedding, sectioned at 6 Jim, and stained with hematoxylin-eosin.
In situ hybridization. Tumors (clones 9 or 24) were fixed by immersion in 4% paraformaldehyde in 0.1 M phosphate, pH 7.2, for 1 h at 4°C. After fixation, specimens were infiltrated overnight with 20% sucrose, frozen, and sectioned on a cryostat at 12 ,m. Sections were thaw mounted onto Vectabond-coated slides (Vector Laboratories, Burlingame, CA), dried, and stored at -70°C. In situ hybridization was performed as described (26) using a 1-kb probe representing residues 924-1920 of the coding region of the human VEGF sequence (9) . For specificity control, adjacent sections were incubated with sense probe.
Immunocvtochemistry. Sections of tumors derived from clone 9 were stained for VEGF by the avidin-biotin-peroxidase method. De VEGF is not an autocrine growthfactor nor does it promote anchorage-independent growth of CHO cells. The addition of purified rhVEGF,65 in a concentration range between 1 and 20 ng/ml had no effect on the final density of parental, vectortransfected, or VEGF-expressing cells (Fig. 3 A) . Growth curves revealed that the proliferation rate of clone 9 was about twofold lower than that of parental cells. Clone 24 proliferated at the same rate as the parental cells. Cells transfected with vector alone exhibited the highest growth rate (Fig. 3 B) .
Cell lines were also tested for their ability to grow in an anchorage-independent manner in soft agar. Figure 2 . Analysis of conditioned media of parental ( 1, 4), vectortransfected (2, 5), or clone 9 (VEGF165) cells (3, 6) . Cells were metabolically labeled as described in Methods. Aliquots of conditioned medium were then subjected to SDS/PAGE gel in both nonreducing (-DTT) and reducing (+DTT) conditions. The gel was then dried and processed for fluorography. site. The tumors were well circumscribed lesions with thin fibrous encapsulation (Fig. 4, A The In situ hybridization. In situ hybridization revealed that the VEGF mRNA was strongly expressed by the majority oftumor cells. Essentially similar results were obtained with tumors originating from either clone 9 or clone 24. Fig. 5 A illustrates the VEGF mRNA expression in a section from a clone 9-derived tumor and adjacent host tissue. VEGF mRNA expression appeared uniform throughout the extent of the lesion. Host tissues and the fibrous capsule surrounding the tumor were invariably negative for VEGF hybridization signal. Higher magnification examination revealed that the hybridization signal was not associated with endothelial cells within the lesion. No appreciable hybridization was observed in sections incubated with sense probe (Fig. 5 B) .
Immunocytochemistry. Approximately 80% of tumor cells in lesions induced by clone 9 demonstrated cytoplasmic and membranous staining for VEGF when probed with a specific monoclonal antibody (Fig. 6 A) . The specificity ofthe reaction was demonstrated by the lack of immunostaining when a control monoclonal antibody was used (Fig. 6 B) .
Ultrastructural analysis. Transmission electron microscopy examination of tumor tissues derived from either clone 9
or clone 24 revealed than most of the capillaries were of the continuous type. Endothelial cells contained plasmalemmal vesicles opening at both apical and basal side. Close examination failed to show any apparent alterations in the ultrastructure in both endothelial cells and pericytes. Fig. 7 illustrates the morphology of a typical capillary from a tumor derived from clone 9.
Discussion
The soft agar provides evidence that the ability to grow in vivo was Therefore, it appears that such an advantage in vivo is acnot related to transformation, at least as assessed by conven- counted for by paracrine mechanisms. This situation is unlike tional in vitro criteria (39 growth factor-alpha (30) , acidic FGF (32), or bFGF fused to a signal peptide (33) which also confer to transfected cells the ability to grow in vivo. These agents induce transformation and are thought to promote tumorigenesis by both autocrine and paracrine mechanisms (30, 32, (42) (43) (44) . We hypothesize that the in vivo growth of VEGF-expressing cells is mediated, at least in part, by the direct angiogenic properties of the growth factor. VEGF has been shown to promote angiogenesis in several in vitro and in vivo systems (8-10, 14, 22) . That VEGF was truly available to elicit such effects is demonstrated by the high expression of the mRNA and by the immunocytochemical localization of the VEGF protein in the majority of cells in the lesion. The invasion of capillaries is expected to result in the delivery of blood-borne factors and nutrients which would in turn trigger and maintain cell proliferation. That this model is plausible is suggested not only by studies on tumor progression and growth (6, 7) but also by physiological angiogenesis like that occurring in the ovarian follicle. The process of follicle selection requires a mechanism by which a single follicle continues to survive and mature. A strong correlation exists between density of microvessels and follicular dominance in the primate ovary (45) . The higher capillary density results in a greater delivery to the dominant follicle of gonadotropins, plasma factors, and nutrients that in turn support growth and differentiation, while nondominant follicles undergo atresia. In this context, it is very interesting to observe that recent studies have provided evidence that only the selected follicle contains cells that intensely express the VEGF mRNA in the primate ovary (26) .
A further mechanism that might potentially contribute to the proliferative process is angiogenesis and/or mitogenesis mediated by macrophage-derived factors. Recent studies provided evidence that VEGF has the ability to promote monocyte chemotaxis (46) . Infiltration of macrophages and other inflammatory cells was observed in VEGF-expressing tumors, although it was not prominent in most of the lesions.
It is important to emphasize that VEGF expression, although sufficient to promote a growth process, did not lead to malignant proliferation or to metastasis. The lesions formed by VEGF-expressing CHO cells were essentially benign and did not grow beyond a relatively small size. This is in agreement with the notion that stimulation of angiogenesis is necessary but not sufficient for malignant growth (3) .
Since VEGF/vascular permeability factor has been also characterized as a protein associated with tumor vascular permeability (13) (14) (15) (16) , and, more recently, it has been implicated in the development and maintenance of fenestrations in capillaries (27) , it would be of significant interest to elucidate the ultrastructure of microvessels after continual exposure to the growth factor. Proliferative lesions derived from transfected cells provide a unique opportunity. However, capillaries in tumors expressing either secreted molecular species of VEGF did not exhibit fenestrations or other ultrastructural features consistent with unusually high permeability, such as intercellular gaps, high number of pinocytotic vesicles, or abnormalities in the junctional complex (47) (48) (49) (50) . The endothelium was of the continuous type and its ultrastructural features were consistent with a normal capillary (49) . Even though tracer studies would be required to provide a direct measurement ofvascular permeability (51, 52) , very little or nothing in the morphology of the lesions was consistent with leakage. These findings clearly do not rule out the possibility that VEGF may promote extravasation in different experimental circumstances or that leakage may have occurred in the tumors at an earlier time point. The hypothesis that this factor is a mediator of vascular permeability was based largely on its potent activity in the Miles assay (28) . Further studies are required to fully assess the significance and relevance of this activity.
In conclusion, our findings provide evidence that expression of VEGF confers on cells a growth advantage in vivo and suggest that a purely paracrine mediator may be sufficient to trigger the complex chain of events leading to a proliferative process. Since VEGF is a widely distributed secreted protein, such an inductive mechanism has the potential to operate in a variety of physiological circumstances such as normal growth, ovarian function, or wound healing. Furthermore, a variety of tumor cells express the VEGF mRNA at high level and secrete VEGF ( 12) , suggesting that this soluble protein may facilitate tumor growth through its direct angiogenic effects. Our findings are consistent with this hypothesis.
